All 1 tracked stories fall under one category: pharma. Agenus Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Stephens Inc. appears in 1 tracked Biotech story from August 8, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Stephens Inc.
All 1 tracked stories fall under one category: pharma. Agenus Inc. is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. Stephens Inc. appears in 1 tracked Biotech story from August 8, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Stephens Inc.. Shared-story counts are live from our verified record — not editorial picks.
Wall Street Zen upgraded biotech Agenus to buy despite a massive Q1 earnings miss, as the stock surged 189% from its 52-week low. Mixed analyst views and a $30 HC Wainwright target highlight the speculative upside in immuno-oncology.